Vaxcyte (PCVX) Other Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Other Non-Current Assets data on file, last reported at $155.5 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $155.5 million, up 11692.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.5 million (up 11692.19% YoY), and the FY2025 annual result was $118.8 million, up 84.66% from the prior year.
• Other Non-Current Assets improved to $155.5 million in Q1 2026 per PCVX's latest filing, from $118.8 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $155.5 million in Q1 2026 and troughed at $871000.0 in Q3 2022.
• A 5-year average of $27.2 million and a median of $1.5 million in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets tumbled 72.01% in 2024, then soared 11692.19% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $871000.0 in 2022, then increased by 26.64% to $1.1 million in 2023, then surged by 5734.9% to $64.4 million in 2024, then soared by 84.66% to $118.8 million in 2025, then jumped by 30.87% to $155.5 million in 2026.
• Business Quant data shows PCVX's Other Non-Current Assets at $155.5 million in Q1 2026, $118.8 million in Q4 2025, and $1.5 million in Q3 2025.